Earnings results might Drive Its Stock Price NASDAQ:CPIX, NASDAQ:NLTX, NASDAQ:EYEG, NASDAQ:CGEN

0
95

CUMBERLAND PHARMACEUTICALS (NASDAQ:CPIX) EARNINGS INFORMATION (NASDAQ:CPIX)

Cumberland Pharmaceuticals last announced its earnings results on May 10th, 2021. The specialty pharmaceutical company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.14. Cumberland Pharmaceuticals has generated $0.23 earnings per share over the last year. Cumberland Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, August 10th, 2021 based off prior year’s report dates.

IS CUMBERLAND PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:CPIX)

1 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Cumberland Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals

NEOLEUKIN THERAPEUTICS (NASDAQ:NLTX) EARNINGS INFORMATION (NASDAQ:NLTX)

Neoleukin Therapeutics last issued its quarterly earnings data on May 13th, 2021. The reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.04. Neoleukin Therapeutics has generated ($0.75) earnings per share over the last year. Neoleukin Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, August 11th, 2021 based off prior year’s report dates.

IS NEOLEUKIN THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:NLTX)

6 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Neoleukin Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Neoleukin Therapeutics stock.
Neoleukin Therapeutics

EYEGATE PHARMACEUTICALS (NASDAQ:EYEG) EARNINGS INFORMATION (NASDAQ:EYEG)

EyeGate Pharmaceuticals last released its earnings data on May 12th, 2021. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. EyeGate Pharmaceuticals has generated ($2.23) earnings per share over the last year. EyeGate Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, August 5th, 2021 based off prior year’s report dates.

IS EYEGATE PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:EYEG)

2 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for EyeGate Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” EyeGate Pharmaceuticals stock.
EyeGate Pharmaceuticals

COMPUGEN (NASDAQ:CGEN) EARNINGS INFORMATION (NASDAQ:CGEN)

Compugen last announced its earnings results on May 13th, 2021. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. Compugen has generated ($0.43) earnings per share over the last year. Compugen has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, July 29th, 2021 based off prior year’s report dates.

IS COMPUGEN A BUY RIGHT NOW? (NASDAQ:CGEN)

4 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Compugen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Compugen stock.
Compugen